DBV Technologies SA - ADR (OQ:DBVT)

Business Focus: Specialty & Advanced Pharmaceuticals

Get the company report for the most recent outlook updated daily

Jun 05, 2024 04:30 pm ET

DBV Technologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Châtillon, France, June 5, 2024 DBV Technologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage...

Jun 04, 2024 04:30 pm ET

Information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2024

Information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR...

May 31, 2024 09:51 am ET

DBV Technologies Announces Plan to Implement ADS Ratio Change

Châtillon, France, May 31, 2024 DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), a clinical-stage biopharmaceutical company focused on...

May 30, 2024 04:30 pm ET

DBV Technologies to Participate in Upcoming EAACI 2024 Congress

Châtillon, France, May 30, 2024 DBV Technologies to Participate in Upcoming EAACI 2024 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment...

May 17, 2024 04:30 pm ET

DBV Technologies Announces Plan to Implement ADS Ratio Change

Châtillon, France, May 17, 2024 DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), a clinical-stage biopharmaceutical company focused on...

May 16, 2024 04:30 pm ET

DBV Technologies Announces Results of its 2024 Combined General Meeting

Châtillon, France, May 16, 2024 DBV Technologies Announces Results of its 2024 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the...

May 09, 2024 04:30 pm ET

DBV Technologies to Participate in Upcoming Investor Conferences

Montrouge, France, May 9, 2024 DBV Technologies to Participate in Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company...

May 07, 2024 04:30 pm ET

DBV Technologies Reports First Quarter 2024 Financial Results and Business Update

Montrouge, France, May 7, 2024 DBV Technologies Reports First Quarter 2024 Financial Results and Business Update VITESSE enrollment on track to screen last patient by Q3 2024Appointment of Robert Pietrusko, PharmD to Chief Regulatory OfficerQ1...

Apr 25, 2024 04:30 pm ET

Combined General Meeting of May 16, 2024

Châtillon, France, April 25, 2024 Combined General Meeting of May 16, 2024 Procedures for Obtaining Information and Preparatory Documents for the Combined General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market:...

Apr 04, 2024 04:43 pm ET

Information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2024

...

Mar 08, 2024 09:33 am ET

DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document

Montrouge, France, March 8, 2024 DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage...

Mar 07, 2024 04:30 pm ET

DBV Technologies Reports Full Year 2023 Financial Results and Business Update

Montrouge, France, March 7, 2024 DBV Technologies Reports Full Year 2023 Financial Results and Business Update Advanced Viaskin™ Peanut clinical development programs in peanut-allergic toddlers (1 through 3 years old) and children (4 through 7...

Mar 04, 2024 04:30 pm ET

DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024

Montrouge, France, March 4, 2024 DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical...

Feb 20, 2024 04:30 pm ET

DBV Technologies to Participate in Upcoming AAAAI 2024 Congress

Montrouge, France, February 20 2024 DBV Technologies to Participate in Upcoming AAAAI 2024 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 –NASDAQ: DBVT), a clinical-stage biopharmaceutical company focused on treatments for food...

Jan 16, 2024 04:30 pm ET

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

AMF Regulated InformationMontrouge, France, January 16, 2024 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage...

Dec 04, 2023 04:30 pm ET

Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2023

Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN...

Nov 09, 2023 04:30 pm ET

DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers

Montrouge, France, November 9, 2023 DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers Viaskin Peanut showed improvement between months 12 and 24 of...

Nov 06, 2023 04:30 pm ET

Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2023

Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE...

Nov 02, 2023 04:30 pm ET

DBV Technologies to Present New Data at ACAAI 2023

Montrouge, France, November 2, 2023 DBV Technologies to Present New Data at ACAAI 2023 New data to include late-breaking abstract detailing interim 12-month results from the ongoing Phase 3 open-label extension to the EPITOPE trial (EPOPEX) of...

Oct 31, 2023 04:30 pm ET

DBV Technologies Receives Requested Feedback from FDA on Protocol Design Elements for COMFORT Safety Studies and Reports Third Quarter 2023 Financial Results

Montrouge, France, October 31, 2023 DBV Technologies Receives Requested Feedback from FDA on Protocol Design Elements for COMFORT Safety Studies and Reports Third Quarter 2023 Financial Results DBV has received written feedback from the U.S. Food...

Oct 27, 2023 04:30 pm ET

DBV Technologies to Report Third Quarter 2023 Financial Results and Business Update

Montrouge, France, October 27, 2023 DBV Technologies to Report Third Quarter 2023 Financial Results and Business Update DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company,...

Oct 16, 2023 02:00 am ET

DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer

Montrouge, France, October 16, 2023 DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical...

Oct 05, 2023 04:30 pm ET

Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2023

Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE...

Sep 05, 2023 04:30 pm ET

DBV Technologies to Participate in Upcoming Investor Conference

Montrouge, France, September 5, 2023 DBV Technologies to Participate in Upcoming Investor Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the...

Jul 31, 2023 04:25 pm ET

DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial Results

Montrouge, France, July 31, 2023 DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial Results Received feedback from U.S. Food and Drug...

Jul 25, 2023 04:30 pm ET

DBV Technologies to Report First Half 2023 Financial Results and Provide a Corporate Update

Montrouge, France, July 25, 2023 DBV Technologies to Report First Half 2023 Financial Results and Provide a Corporate Update DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical...

Jul 19, 2023 04:30 pm ET

Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2023

Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE...

Jul 10, 2023 04:30 pm ET

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

AMF Regulated InformationMontrouge, France, July 10, 2023 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage...

Jun 16, 2023 04:30 pm ET

Monthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2023

Monthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris...

Jun 16, 2023 09:31 am ET

Thinking about buying stock in Applied UV, CBAK Energy Technology, Novavax, C3.ai, or DBV Technologies?

NEW YORK, June 16, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AUVI, CBAT, NVAX, AI, and DBVT.

Jun 08, 2023 04:30 pm ET

DBV Technologies to Participate in Upcoming EAACI Congress 2023

Montrouge, France, June 8, 2023 DBV Technologies to Participate in Upcoming EAACI Congress 2023 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming...

Jun 06, 2023 05:00 pm ET

DBV Technologies to Participate in Upcoming Investor Conference

Montrouge, France, June 06, 2023 DBV Technologies to Participate in Upcoming Investor Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its...

May 10, 2023 05:30 pm ET

DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin™ Peanut in Toddlers

Montrouge, France, May 10, 2023 DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin™ Peanut in Toddlers The New England Journal of Medicine (NEJM) published results that...

May 09, 2023 04:30 pm ET

DBV Technologies to Participate in Upcoming Investor Conference

Montrouge, France, May 9, 2023 DBV Technologies to Participate in Upcoming Investor Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its...

May 04, 2023 04:30 pm ET

DBV Technologies Reports First Quarter 2023 Financial Results

Montrouge, France, May 4, 2023 DBV Technologies Reports First Quarter 2023 Financial Results DBV closes Q1 2023 with cash and cash equivalents of $192.3 million. DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock...

Apr 19, 2023 05:09 pm ET

DBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 – 3 Years After Receiving Pre-BLA Responses from FDA

Montrouge, France, April 19, 2023 DBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 – 3 Years After Receiving Pre-BLA Responses from FDA The FDA confirmed that the Company’s Phase 3 EPITOPE study met the pre-specified...

Apr 12, 2023 04:30 pm ET

DBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General Meeting

Montrouge, France, April 12, 2023 DBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General Meeting Shareholders Approved All Proposed Resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock...

Mar 24, 2023 04:30 pm ET

Ordinary and Extraordinary General Meeting of April 12, 2023

Montrouge, France, March 24, 2023 Ordinary and Extraordinary General Meeting of April 12, 2023 Procedures for Obtaining Information and Preparatory Documents for the General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq...

Mar 13, 2023 01:30 am ET

DBV Technologies Update

Montrouge, France, March 13, 2023 DBV Technologies Update DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), a clinical-stage biopharmaceutical company, informs its investors that it does not hold cash deposits or...

Mar 07, 2023 04:30 pm ET

DBV Technologies Announces First Patient Screened in VITESSE Phase 3 Clinical Trial in Peanut-Allergic Children 4 – 7 Years Old

Montrouge, France, March 7, 2023 DBV Technologies Announces First Patient Screened in VITESSE Phase 3 Clinical Trial in Peanut-Allergic Children 4 – 7 Years Old First patient screened at Midwest Allergy Sinus Asthma in Normal, Illinois VITESSE is...

Mar 02, 2023 05:30 pm ET

DBV Technologies announces filing of 2022 Annual Report on Form 10-K and 2022 Universal Registration Document

Montrouge, France, March 2, 2023 DBV Technologies announces filing of 2022 Annual Report on Form 10-K and 2022 Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a...

Mar 02, 2023 04:30 pm ET

DBV Technologies Reports Full Year 2022 Financial Results and Business Update

Montrouge, France, March 2, 2023 DBV Technologies Reports Full Year 2022 Financial Results and Business Update DBV completed EVOLVE, a 12-week caregiver and patient user experience study of the modified Viaskin Peanut patch in peanut-allergic...

Feb 27, 2023 01:30 am ET

DBV Technologies to Report Full Year 2022 Financial Results and Business Updates on March 2, 2023

Montrouge, France, February 27, 2023 DBV Technologies to Report Full Year 2022 Financial Results and Business Updates on March 2, 2023 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage...

Feb 21, 2023 04:30 pm ET

DBV Technologies to Participate in Upcoming AAAAI 2023 Congress

Montrouge, France, February 21, 2023 DBV Technologies to Participate in Upcoming AAAAI 2023 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today...

Feb 10, 2023 04:30 pm ET

DBV Technologies to Participate in Upcoming Investor Conference

Montrouge, France, February 10, 2023 DBV Technologies to Participate in Upcoming Investor Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its...

Jan 23, 2023 04:30 pm ET

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

AMF Regulated InformationMontrouge, France, January 23, 2023 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage...

Jan 04, 2023 04:30 pm ET

Monthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2022

...

Dec 23, 2022 09:41 am ET

Thinking about buying stock in Core Scientific, DBV Technologies, Gaotu Techedu, New Oriental Education, or Ardelyx?

NEW YORK, Dec. 23, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CORZ, DBVT, GOTU, EDU, and ARDX.

Dec 23, 2022 01:30 am ET

DBV Technologies Announces FDA Has Lifted Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial

Montrouge, France, December 23, 2022 DBV Technologies Announces FDA Has Lifted Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial DBV expects to initiate patient screening in Q1 2023 with the last patient screened by 1H 2024 and topline...

Dec 08, 2022 04:30 pm ET

Monthly information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2022

...

Nov 22, 2022 04:30 pm ET

DBV Technologies to Participate in Upcoming Investor Conference

Montrouge, France, November 22, 2022 DBV Technologies to Participate in Upcoming Investor Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today...

Nov 09, 2022 01:30 am ET

DBV Technologies to Highlight New Clinical Data at ACAAI 2022

Montrouge, France, November 9, 2022 DBV Technologies to Highlight New Clinical Data at ACAAI 2022 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that...

Nov 03, 2022 04:30 pm ET

DBV Technologies Reports Third Quarter Financial Results and Business Update

Montrouge, France, November 3, 2022 DBV Technologies Reports Third Quarter Financial Results and Business Update DBV closes Q3 with a cash balance of $213MDBV continues to practice budget discipline measures; cash used in operating activities...

Oct 31, 2022 04:30 pm ET

DBV Technologies to Report Third Quarter 2022 Financial Results and Provide a Business Update

Montrouge, France, October 31, 2022 DBV Technologies to Report Third Quarter 2022 Financial Results and Provide a Business Update DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage...

Oct 20, 2022 04:30 pm ET

Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2022

Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2022 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE...

Oct 10, 2022 07:20 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DBV Technologies S.A. - DBVT

NEW YORK, Oct. 10, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DBV Technologies S.A. (""DBV" or the "Company") (NASDAQ: DBVT). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Oct 06, 2022 07:08 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DBV Technologies S.A. - DBVT

Pomerantz LLP is investigating claims on behalf of investors of DBV Technologies S.A. (“DBV” or the “Company”) (NASDAQ: DBVT). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...

Oct 03, 2022 04:30 pm ET

DBV Technologies Announces Appointment of New Chair of its Audit Committee and Appointment of Daniele Guyot-Caparros to Board of Directors

Montrouge, France, October 3, 2022 DBV Technologies Announces Appointment of New Chair of its Audit Committee and Appointment of Daniele Guyot-Caparros to Board of Directors DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock...

Oct 03, 2022 12:25 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DBV Technologies S.A. - DBVT

NEW YORK, Oct. 3, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DBV Technologies S.A. (""DBV" or the "Company") (NASDAQ: DBVT). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Sep 27, 2022 05:30 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DBV Technologies S.A. - DBVT

Pomerantz LLP is investigating claims on behalf of investors of DBV Technologies S.A. (“”DBV” or the “Company”) (NASDAQ: DBVT). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...

Sep 21, 2022 05:45 pm ET

DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial

Montrouge, France, September 21, 2022 DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced...

Sep 07, 2022 04:30 pm ET

DBV Technologies Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Viaskin Peanut Patch in Peanut -Allergic Children Ages 4 to 7 Years

Montrouge, France, September 7, 2022 DBV Technologies Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Viaskin Peanut Patch in Peanut -Allergic Children Ages 4 to 7 Years DBV has finalized the VITESSE protocol after productive...

Sep 02, 2022 04:30 pm ET

DBV Technologies to Present at Upcoming Investor Conferences

Montrouge, France, September 2, 2022 DBV Technologies to Present at Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that...

Aug 10, 2022 04:50 pm ET

Aquestive Therapeutics Strengthens Team to Align with Strategic Focus on Allergy Space

Aquestive Therapeutics, Inc. (Nasdaq: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today the appointments of...

Aug 01, 2022 04:30 pm ET

DBV Technologies Reports Second Quarter 2022 Financial Results

Montrouge, France, August 1, 2022 DBV Technologies Reports Second Quarter 2022 Financial Results DBV closes Q2 with a cash balance of $248M following recent ATM and PIPE offeringsDBV continues to practice budget discipline measures; cash used in...

Jul 27, 2022 04:30 pm ET

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

AMF REGULATED INFORMATIONMontrouge, France, July 27, 2022 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage...

Jul 20, 2022 04:30 pm ET

Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2022

Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2022 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris...

Jun 28, 2022 06:15 pm ET

DBV Technologies to Participate in Upcoming EAACI 2022 Congress

Montrouge, France, June 28, 2022 DBV Technologies to Participate in Upcoming EAACI 2022 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced...

Jun 21, 2022 08:30 am ET

Thinking about buying stock in Clovis Oncology, Advent Technologies, DBV Technologies, Powerbridge Technologies, or Spirit Airlines?

NEW YORK, June 21, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLVS, ADN, DBVT, PBTS, and SAVE.

Jun 16, 2022 01:30 am ET

DBV Technologies to Present at the JMP Securities Life Sciences Conference in New York

Montrouge, France, June 16, 2022 DBV Technologies to Present at the JMP Securities Life Sciences Conference in New York DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company,...

Jun 09, 2022 02:55 am ET

DBV Technologies Announces Private Placement Financing of $194 Million

Montrouge, France, June 9, 2022 DBV Technologies Announces Private Placement Financing of $194 Million DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Global Select Market: DBVT), a clinical-stage biopharmaceutical company, today...

Jun 08, 2022 08:35 am ET

Thinking about buying stock in Aldeyra Therapeutics, Redbox Entertainment, Torrid Holdings, DBV Technologies, or Stealth BioTherapeutics?

NEW YORK, June 8, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ALDX, RDBX, CURV, DBVT, and MITO.

Jun 07, 2022 04:30 pm ET

DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers

Montrouge, France, June 7, 2022 DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers 67.0% of subjects treated with Viaskin Peanut 250 µg met response criteria at 12 months,...

May 17, 2022 04:30 pm ET

Monthly information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2022

Monthly information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2022 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE...

May 12, 2022 04:30 pm ET

DBV Technologies Announces Results of Its 2022 Ordinary and Extraordinary General Meeting

Montrouge, France, May 12, 2022 DBV Technologies Announces Results of Its 2022 Ordinary and Extraordinary General Meeting Shareholders Approved All Proposed Resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock...

May 04, 2022 07:30 pm ET

DBV Technologies Completes ADSs Sale of an amount of $15.3 million on Nasdaq through its At-The-Market program (ATM)

Montrouge, France, May 5, 2022 DBV Technologies Completes ADSs Sale of an amount of $15.3 million on Nasdaq through its At-The-Market program (ATM) DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Global Select Market: DBVT) (the...

May 04, 2022 10:45 am ET

Thinking about buying stock in DBV Technologies, IONQ, Borqs Technologies, Gran Tierra Energy, or Coty?

NEW YORK, May 4, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DBVT, IONQ, BRQS, GTE, and COTY.

May 02, 2022 05:00 pm ET

DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq

Montrouge, France, May 2, 2022 DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Global Select Market: DBVT) (the “Company”), a clinical-stage biotechnological...

May 02, 2022 04:00 pm ET

DBV Technologies Reports Recent Business Developments and First Quarter 2022 Financial Results

Montrouge, France, May 2, 2022 DBV Technologies Reports Recent Business Developments and First Quarter 2022 Financial Results The U.S. Food and Drug Administration (FDA) has granted DBV Technologies a Type C meeting to align on the new Viaskin...

Apr 25, 2022 07:30 pm ET

Correction: DBV Technologies to Report First Quarter 2022 Financial Results and Recent Business Developments

Montrouge, France, April 26, 2022DBV Technologies to Report First Quarter 2022 Financial Results and Recent Business Developments DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage...

Apr 25, 2022 04:30 pm ET

DBV Technologies to Report First Quarter 2022 Financial Results and Recent Business Developments

Montrouge, France, April 25, 2022DBV Technologies to Report First Quarter 2022 Financial Results and Recent Business Developments DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage...

Apr 21, 2022 04:30 pm ET

Ordinary and Extraordinary General Meeting of May 12, 2022

Montrouge, France, April 21, 2022Ordinary and Extraordinary General Meeting of May 12, 2022 Procedures for Obtaining Preparatory Documents for the General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market:...

Apr 14, 2022 04:30 pm ET

Monthly information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2022

Monthly information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2022 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)...

Mar 14, 2022 04:30 pm ET

DBV Technologies to Present at the Oppenheimer’s 32nd Annual Healthcare Conference

Montrouge, France, March 14, 2022DBV Technologies to Present at the Oppenheimer’s 32nd Annual Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company,...

Mar 11, 2022 04:30 pm ET

Monthly information regarding the total number of voting rights and total number of shares of the Company as of February 28, 2022

Monthly information regarding the total number of voting rights and total number of shares of the Company as of February 28, 2022 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris...

Mar 09, 2022 04:30 pm ET

DBV Technologies Announces Filing of 2021 Annual Report on Form 10-K and 2021 Universal Registration Document

Montrouge, France, March 9, 2022 DBV Technologies Announces Filing of 2021 Annual Report on Form 10-K and 2021 Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage...

Mar 03, 2022 04:15 pm ET

DBV Technologies Reports Full Year 2021 Financial Results and Recent Business Updates

Montrouge, France, March 3, 2022 DBV Technologies Reports Full Year 2021 Financial Results and Recent Business Updates mVP Pivotal Protocol Complete and Ready for Submission to FDADBV Continues to Engage in Productive Exchanges with FDACash Runway...

Feb 24, 2022 04:30 pm ET

DBV Technologies to Report Full Year 2021 Financial Results and Business Updates on March 3, 2022

Montrouge, France, February 24, 2022 DBV Technologies to Report Full Year 2021 Financial Results and Business Updates on March 3, 2022 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage...

Feb 22, 2022 04:30 pm ET

DBV Technologies to Participate in Upcoming AAAAI 2022 Congress

Montrouge, France, February 22, 2022 DBV Technologies to Participate in Upcoming AAAAI 2022 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced...

Feb 14, 2022 04:30 pm ET

DBV Technologies to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Montrouge, France, February 14, 2022 DBV Technologies to Present at the 11th Annual SVB Leerink Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical...

Feb 09, 2022 04:30 pm ET

Monthly information regarding the total number of voting rights and total number of shares of the Company as of January 31, 2022

Monthly information regarding the total number of voting rights andtotal number of shares of the Company as of January 31, 2022 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market: NYSE...

Jan 21, 2022 04:30 pm ET

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

AMF REGULATED INFORMATIONMontrouge, France, January 21, 2022 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage...

Jan 12, 2022 04:30 pm ET

Monthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2021

Monthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris...

Jan 07, 2022 01:30 am ET

DBV Technologies to Present at the H.C. Wainwright BioConnect 2022 Conference

Montrouge, France, January 7, 2022 DBV Technologies to Present at the H.C. Wainwright BioConnect 2022 Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today...

Dec 22, 2021 07:36 am ET

Thinking about buying stock in BioRestorative Therapies, DBV Technologies, Frontline, Galera Therapeutics, or Can Fite Biopharma?

NEW YORK, Dec. 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BRTX, DBVT, FRO, GRTX, and CANF.

Dec 20, 2021 04:15 pm ET

DBV Technologies Provides Update on Investigational Viaskin™ Peanut

Montrouge, France, December 20, 2021 DBV Technologies Provides Update on Investigational Viaskin™ Peanut DBV Technologies S.A. (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today...

Dec 10, 2021 04:30 pm ET

Monthly information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2021

Monthly information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext...

Nov 24, 2021 01:30 am ET

DBV Technologies to Participate in an Upcoming Investor Conference

Montrouge, France, November 24, 2021 DBV Technologies to Participate in an Upcoming Investor Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced...

Nov 04, 2021 04:30 pm ET

Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2021

Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE...

Nov 01, 2021 03:34 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DBV Technologies S.A. - DBVT

Nov 01, 2021 02:30 am ET

DBV Technologies to Highlight New Long-term Data from REALISE Trial at ACAAI 2021

Montrouge, France, November 1, 2021 DBV Technologies to Highlight New Long-term Data from REALISE Trial at ACAAI 2021 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company,...

Oct 26, 2021 04:15 pm ET

DBV Technologies Reports Third Quarter 2021 Financial Results and Recent Regulatory Developments

Montrouge, France, October 26, 2021 DBV Technologies Reports Third Quarter 2021 Financial Results and Recent Regulatory Developments DBV Technologies S.A. (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage...

Oct 12, 2021 04:30 pm ET

Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2021

Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext...

Sep 08, 2021 04:00 pm ET

Monthly information regarding the total number of voting rights and total number of shares of the Company as of August 31, 2021

Monthly information regarding the total number of voting rights and total number of shares of the Company as of August 31, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris...

Aug 31, 2021 01:30 am ET

DBV Technologies to Participate at Upcoming Investor Conferences

Montrouge, France, August 31, 2021 DBV Technologies to Participate at Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that...

Aug 20, 2021 04:15 pm ET

Beyond Air® Announces CFO Transition

Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...

Aug 09, 2021 04:30 pm ET

Monthly information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2021

Monthly information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris...

Aug 06, 2021 04:30 pm ET

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

AMF REGULATED INFORMATIONMontrouge, France, August 6, 2021 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage...

Aug 02, 2021 04:15 pm ET

DBV Technologies Reports Second Quarter 2021 Financial Results and Recent Business Developments

Montrouge, France, August 2, 2021 DBV Technologies Reports Second Quarter 2021 Financial Results and Recent Business Developments Business Highlights: Viaskin Peanut US: DBV submitted the protocol for the 6-month adhesion and safety study...

Jul 26, 2021 04:30 pm ET

DBV Technologies to Report First Half 2021 Financial Results and Business Updates on August 2, 2021

Montrouge, France, July 26, 2021 DBV Technologies to Report First Half 2021 Financial Results and Business Updates on August 2, 2021 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage...

Jul 07, 2021 04:30 pm ET

Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2021

Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext...

Jun 15, 2021 04:30 pm ET

Monthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2021

Monthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris...

Jun 02, 2021 01:30 am ET

DBV Technologies to Present at Upcoming Investor Conferences

Montrouge, France, June 2, 2021 DBV Technologies to Present at Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that...

May 19, 2021 04:30 pm ET

DBV Technologies Announces Results of its 2021 Ordinary and Extraordinary General Meeting and the Appointment of Dr. Adora Ndu, Pharm.D., J.D., and Dr. Ravi Madduri Rao, M.D., Ph.D., as Members of its

Montrouge, France, May 19, 2021 DBV Technologies Announces Results of its 2021 Ordinary and Extraordinary General Meeting and the Appointment of Dr. Adora Ndu, Pharm.D., J.D., and Dr. Ravi Madduri Rao, M.D., Ph.D., as Members of its Board of...

May 17, 2021 04:30 pm ET

Monthly information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2021

Monthly information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN...

May 05, 2021 05:00 pm ET

DBV Technologies Announces Filing of its First Form 10-Q for the First Quarter of 2021

Montrouge, France, May 5, 2021 DBV Technologies Announces Filing of its First Form 10-Q for the First Quarter of 2021 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company,...

May 03, 2021 01:30 am ET

DBV Technologies Reports Q1 2021 Financial Results

Montrouge, France, May 3, 2021 DBV Technologies Reports Q1 2021 Financial Results DBV Technologies S.A. (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported financial...

Apr 29, 2021 01:30 am ET

DBV Technologies to Participate in Upcoming Investor Conferences

Montrouge, France, April 29, 2021 DBV Technologies to Participate in Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its...

Apr 28, 2021 04:30 pm ET

Monthly information regarding the total number of voting rights and total number of shares of the Company

Monthly information regarding the total number of voting rights and total number of shares of the Company (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code:...

Apr 28, 2021 01:30 am ET

Ordinary and Extraordinary General Meeting of May 19, 2021 to be Held in Closed Virtual Session Due to COVID-19 Pandemic

Montrouge, France, April 28, 2021 Ordinary and Extraordinary General Meeting of May 19, 2021 to be Held in Closed Virtual Session Due to COVID-19 Pandemic DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a...

Apr 02, 2021 04:30 pm ET

DBV Technologies Announces Appointment of Timothy E. Morris to Board of Directors

Montrouge, France, April 2, 2021DBV Technologies Announces Appointment of Timothy E. Morris to Board of Directors DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company,...

Apr 01, 2021 06:30 pm ET

Monthly information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2021

Monthly information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN...

Mar 26, 2021 04:30 pm ET

DBV Technologies Announces a New Chair of its Audit Committee and Date of its Annual General Meeting

Montrouge, France, March 26, 2021 DBV Technologies Announces a New Chair of its Audit Committee and Date of its Annual General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage...

Mar 17, 2021 06:30 pm ET

DBV Technologies Announces Filing of 2020 Annual Report on Form 10-K and 2020 Universal Registration Document

Montrouge, France, March 17, 2021 DBV Technologies Announces Filing of 2020 Annual Report on Form 10-K and 2020 Universal Registration Document The Company also announces that it will enter the SBF 120 Index on Euronext DBV Technologies...

Mar 12, 2021 04:30 pm ET

Monthly information regarding the total number of voting rights and total number of shares of the Company as of February 28, 2021

Monthly information regarding the total number of voting rights and total number of shares of the Company as of February 28, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN...

Mar 11, 2021 04:30 pm ET

DBV Technologies Reports Full-Year 2020 Financial Results and Recent Business Developments

Montrouge, France, March 11, 2021 DBV Technologies Reports Full-Year 2020 Financial Results and Recent Business Developments DBV Technologies S.A. (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage...

Mar 05, 2021 04:30 pm ET

DBV Technologies to Participate in the H.C. Wainwright Global Life Sciences Conference

Montrouge, France, March 5, 2021 DBV Technologies to Participate in the H.C. Wainwright Global Life Sciences Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical...

Mar 03, 2021 06:00 pm ET

DBV Technologies Announces Date Change for Reporting Full Year 2020 Financial Results

Montrouge, France, March 3, 2021 DBV Technologies Announces Date Change for Reporting Full Year 2020 Financial Results DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company,...

Mar 01, 2021 01:30 am ET

DBV Technologies to Report Full Year 2020 Financial Results on March 4, 2021

Montrouge, France, March 1, 2020 DBV Technologies to Report Full Year 2020 Financial Results on March 4, 2021 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today...

Feb 24, 2021 01:30 am ET

DBV Technologies to Participate in Upcoming AAAAI 2021 Congress

Montrouge, France, February 24, 2021 DBV Technologies to Participate in Upcoming AAAAI 2021 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced...

Feb 22, 2021 01:30 am ET

DBV Technologies Announces Appointment of Michele F. Robertson as Chief Legal Officer

Montrouge, France, February 22, 2021 DBV Technologies Announces Appointment of Michele F. Robertson as Chief Legal Officer DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical...

Feb 19, 2021 01:30 am ET

DBV Technologies to Participate in SVB Leerink Global Partners Healthcare Conference

Montrouge, France, February 19, 2021 DBV Technologies to Participate in SVB Leerink Global Partners Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical...

Feb 11, 2021 04:30 pm ET

Monthly information regarding the total number of voting rights and total number of shares of the Company as of January 31, 2021

Monthly information regarding the total number of voting rights and total number of shares of the Company as of January 31, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN...

Jan 29, 2021 04:30 pm ET

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

AMF REGULATED INFORMATIONMontrouge, France, January 29, 2021 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage...

Jan 19, 2021 07:30 am ET

Thinking about buying stock in DBV Technologies, Endra Life Sciences, Precision BioSciences, Sorrento Therapeutics, or Aldeyra Therapeutics?

NEW YORK, Jan. 19, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DBVT, NDRA, DTIL, SRNE, and ALDX.

Jan 15, 2021 07:30 am ET

Thinking about buying stock in Obseva SA, DBV Technologies, BlackBerry, Five Prime Therapeutics, or BioNano Genomics?

NEW YORK, Jan. 15, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OBSV, DBVT, BB, FPRX, and BNGO.

Jan 14, 2021 04:30 pm ET

DBV Technologies Provides Update on Investigational Viaskin™ Peanut for Children Ages 4-11 Years

Montrouge, France, January 14, 2020 DBV Technologies Provides Update on Investigational Viaskin™ Peanut for Children Ages 4-11 Years DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage...

Jan 07, 2021 01:30 am ET

DBV Technologies Announces Change in U.S. Reporting Status and Final Approval of Global Restructuring Process

Montrouge, France, January 7, 2021 DBV Technologies Announces Change in U.S. Reporting Status and Final Approval of Global Restructuring Process DBV Technologies S.A. (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a...

Jan 06, 2021 07:30 am ET

Thinking about buying stock in IsoRay, Change Healthcare, DBV Technologies, Hexo Corp, or Orchard Therapeutics?

NEW YORK, Jan. 6, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ISR, CHNG, DBVT, HEXO, and ORTX.

Jan 05, 2021 04:30 pm ET

Monthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2020

Monthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2020 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris...

Dec 15, 2020 04:30 pm ET

Monthly information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2020

Monthly information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2020 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN...

Nov 24, 2020 01:30 am ET

DBV Technologies Announces Leadership Changes

Montrouge, France, November 24, 2020 DBV Technologies Announces Leadership Changes DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Dr. Hugh Sampson...

Nov 11, 2020 04:30 am ET

Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2020

Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2020 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN...

Nov 10, 2020 01:30 am ET

DBV Technologies to Highlight Data on Viaskin™ Peanut Treatment Delivery and Patient Experience at ACAAI 2020

Montrouge, France, November 10, 2020DBV Technologies to Highlight Data on Viaskin™ Peanut Treatment Delivery and Patient Experience at ACAAI 2020 Meeting also will feature virtual industry symposium on managing food allergies amid the COVID-19...

Nov 09, 2020 01:30 am ET

DBV Technologies to Participate in Upcoming Investor Conferences

Montrouge, France, November 9, 2020DBV Technologies to Participate in Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its...

Nov 02, 2020 08:31 am ET

Thinking about buying stock in Endurance Int, Blink Charging, Niu Technologies, DBV Technologies, or FuelCell Energy?

NEW YORK, Nov. 2, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EIGI, BLNK, NIU, DBVT, and FCEL.

Nov 02, 2020 01:30 am ET

DBV Technologies Announces Filing and Validation of Marketing Authorization Application for Viaskin™ Peanut by European Medicines Agency

Montrouge, France, November 2, 2020 DBV Technologies Announces Filing and Validation of Marketing Authorization Application for Viaskin™ Peanut by European Medicines Agency DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock...

Oct 30, 2020 02:30 am ET

DBV Technologies Reports September 30, 2020 Cash Position

Montrouge, France, October 30, 2020 DBV Technologies Reports September 30, 2020 Cash Position DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported its cash...

Oct 08, 2020 04:01 pm ET

Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2020

Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2020 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris...

Sep 15, 2020 04:30 pm ET

Monthly information regarding the total number of voting rights and total number of shares of the Company as of August 31, 2020

Monthly information regarding the total number of voting rights and total number of shares of the Company as of August 31, 2020 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN...

Sep 09, 2020 01:30 am ET

DBV Technologies Announces Leadership Changes

Montrouge, France, September 9, 2020 DBV Technologies Announces Leadership Changes DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Ramzi Benamar,...

Sep 02, 2020 04:30 pm ET

DBV Technologies to Participate in Multiple September Investor Conferences

Montrouge, France, September 2, 2020 DBV Technologies to Participate in Multiple September Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company,...

Aug 12, 2020 04:01 pm ET

Monthly information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2020

Monthly information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2020 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN...

Aug 04, 2020 05:09 pm ET

SHAREHOLDER ALERT: Investigation of DBV Technologies Announced by Holzer & Holzer, LLC

Holzer & Holzer, LLC is investigating whether DBV Technologies S.A. (“DBV Technologies” or the “Company”) (NASDAQ: DBVT) complied with federal securities laws. On August 4, 2020, DBV Technologies announced it had received a CRL letter from the FDA outlining concerns regarding the efficacy and corresponding need for further testing of the Company’s BLA for Viaskin Peanut. The price of DBV Technology’s stock fell following the announcement.

Aug 04, 2020 01:30 am ET

DBV Technologies Receives Complete Response Letter from FDA for Viaskin Peanut BLA in Children Ages 4-11 Years

Montrouge, France, August 4, 2020 DBV Technologies Receives Complete Response Letter from FDA for Viaskin Peanut BLA in Children Ages 4-11 Years DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage...

Jul 31, 2020 01:30 am ET

DBV Technologies Reports First Half 2020 Financial Results

Montrouge, France, July 31, 2020 DBV Technologies Reports First Half 2020 Financial Results DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported first...

Jul 20, 2020 04:01 pm ET

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

Montrouge, France, July 20, 2020 AMF REGULATED INFORMATION Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage...

Jul 15, 2020 04:01 pm ET

Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2020

Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2020 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris...

Jul 10, 2020 09:00 am ET

DBV Technologies Announces Publication of PEOPLE Phase III Open-Label Extension Study Evaluating Viaskin Peanut in The Journal of Allergy and Clinical Immunology

Montrouge, France, July 7, 2020 DBV Technologies Announces Publication of PEOPLE Phase III Open-Label Extension Study Evaluating Viaskin Peanut in The Journal of Allergy and Clinical Immunology PEOPLE is the largest long-term peanut allergy...

Jun 26, 2020 02:30 am ET

DBV Technologies Provides Operational and Business Update

Montrouge, France, June 26, 2020 DBV Technologies Provides Operational and Business Update BLA review of Viaskin Peanut for the treatment of peanut allergy in children ages 4-11 years ongoing Company to immediately initiate restructuring...

Jun 11, 2020 04:01 pm ET

Monthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2020

Monthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2020 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code:...

Jun 04, 2020 04:30 pm ET

DBV Technologies to Present Data on Epicutaneous Immunotherapy and Food Allergy Quality of Life at EAACI Digital Congress 2020

Montrouge, France, June 4, 2020 DBV Technologies to Present Data on Epicutaneous Immunotherapy and Food Allergy Quality of Life at EAACI Digital Congress 2020 Virtual presentations will include data about children with and without multiple food...

Jun 02, 2020 04:30 pm ET

DBV Technologies To Present at the Goldman Sachs 41st Annual Global Healthcare Conference

Montrouge, France, June 2, 2020 DBV Technologies To Present at the Goldman Sachs 41st Annual Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical...

May 12, 2020 04:01 pm ET

Information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2020

Information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2020 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR...

Apr 30, 2020 04:01 pm ET

DBV Technologies Reports March 31, 2020 Cash Position

Montrouge, France, April 30, 2020 DBV Technologies Reports March 31, 2020 Cash Position DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its cash and...

Apr 20, 2020 04:01 pm ET

DBV Technologies Announces Results of its 2020 Ordinary and Extraordinary General Meeting

Montrouge, France, April 20, 2020 DBV Technologies Announces Results of its 2020 Ordinary and Extraordinary General Meeting Shareholders approve all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market:...

Apr 15, 2020 06:00 am ET

Monthly information regarding the total number of voting rights and total number of shares of the Company

Monthly information regarding the total number of voting rights and total number of shares of the Company...

Apr 10, 2020 04:01 pm ET

Ordinary and Extraordinary General Meeting of April 20, 2020 to be Held in Closed Virtual Session Due to COVID-19 Pandemic

Montrouge, France, April 10, 2020 Ordinary and Extraordinary General Meeting of April 20, 2020 to be Held in Closed Virtual Session Due to COVID-19 Pandemic DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a...

Mar 30, 2020 04:01 pm ET

Ordinary and Extraordinary General Meeting of April 20, 2020

Montrouge, France, March 30, 2020 Ordinary and Extraordinary General Meeting of April 20, 2020 Procedures for Obtaining Preparatory Documents for the General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock...

Mar 26, 2020 11:00 am ET

Monthly information regarding the total number of voting rights and total number of shares of the Company

...

Mar 20, 2020 04:15 pm ET

DBV Technologies Announces Filing of 2019 Universal Registration Document and 2019 Annual Report on Form 20-F

Montrouge, France, March 20, 2020 DBV Technologies Announces Filing of 2019 Universal Registration Document and 2019 Annual Report on Form 20-F DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced...

Mar 17, 2020 04:00 pm ET

Monthly information regarding the total number of voting rights and total number of shares of the Company as of February 29, 2020 and March 4, 2020

Monthly information regarding the total number of voting rights and total number of shares of the Company as of February 29, 2020 and March 4, 2020 (Article 223-16 of the General Regulations of the Autorité des Marchés...

Mar 17, 2020 02:51 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DBV Technologies S.A. - DBVT

Mar 16, 2020 04:30 pm ET

DBV Technologies Provides Update on Viaskin Peanut BLA for Children Ages 4-11 Years

Montrouge, France, March 16, 2020 DBV Technologies Provides Update on Viaskin Peanut BLA for Children Ages 4-11 Years Conference call today, March 16, at 5:00 PM ET / 10:00 PM CET DBV Technologies (Euronext: DBV - ISIN:...

Mar 04, 2020 04:30 pm ET

DBV Technologies Reports Full-Year 2019 Financial Results and Provides Business Update

Montrouge, France, March 4, 2020 DBV Technologies Reports Full-Year 2019 Financial Results and Provides Business Update Advisory Committee meeting to be held on May 15, 2020 to discuss the Viaskin Peanut Biologics License Application...

Mar 04, 2020 04:01 pm ET

DBV Technologies Announces Closing of Underwriters’ Option to Purchase Additional Ordinary Shares in the Form of American Depositary Shares in Connection With its Global Offering

Montrouge, France, March 4, 2020 DBV Technologies Announces Closing of Underwriters’ Option to Purchase Additional Ordinary Shares in the Form of American Depositary Shares in Connection With its Global Offering DBV Technologies (the...

Mar 02, 2020 01:30 am ET

DBV Technologies Announces Partial Exercise of Underwriters’ Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares in the Form of American Depositary Shares (A

Montrouge, France, March 2, 2020 DBV Technologies Announces Partial Exercise of Underwriters’ Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares in the Form of American Depositary Shares (ADSs) DBV...

Feb 24, 2020 04:00 pm ET

DBV Technologies to Present Detailed Safety and Efficacy Data of Viaskin Peanut at AAAAI 2020

Montrouge, France, February 24, 2020 DBV Technologies to Present Detailed Safety and Efficacy Data of Viaskin Peanut at AAAAI 2020 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage...

Feb 21, 2020 09:29 am ET

DBV Technologies Announces FDA Advisory Committee Meeting to Review Viaskin Peanut for the Treatment of Peanut Allergy in Children

Montrouge, France, February 21, 2020 DBV Technologies Announces FDA Advisory Committee Meeting to Review Viaskin Peanut for the Treatment of Peanut Allergy in Children DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market:...

Feb 10, 2020 04:00 pm ET

DBV Technologies to Present at the SVB Leerink 9th Annual Global Healthcare Conference

Montrouge, France, February 10, 2020 DBV Technologies to Present at the SVB Leerink 9th Annual Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical...

Feb 06, 2020 08:00 pm ET

Monthly information regarding the total number of voting rights and total number of shares of the Company as of January 31, 2020 and February 4, 2020

Monthly information regarding the total number of voting rights and total number of shares of the Company as of January 31, 2020 and February 4, 2020 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market :...

Feb 06, 2020 04:01 pm ET

DBV Technologies Announces Appointment of Pascal Wotling as Chief Technical Operations Officer

Montrouge, France, February 6, 2020 DBV Technologies Announces Appointment of Pascal Wotling as Chief Technical Operations Officer DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage...

Feb 04, 2020 04:30 pm ET

DBV Technologies Announces Closing of Global Offering

Montrouge, France, February 4, 2020 DBV Technologies Announces Closing of Global Offering DBV Technologies (the “Company”) (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today...

Jan 30, 2020 01:30 am ET

DBV Technologies Announces Pricing of $153.7 million (€139.8 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares

Montrouge, France, January 30, 2020 DBV Technologies Announces Pricing of $153.7 million (€139.8 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares DBV Technologies (the “Company”) (Euronext: DBV –...

Jan 29, 2020 04:05 pm ET

DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and Reports December 31, 2019 Cash Position

Montrouge, France, January 29, 2020 DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and Reports December 31, 2019 Cash Position DBV Technologies...

Jan 15, 2020 04:00 pm ET

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

AMF REGULATED INFORMATIONMontrouge, France, January 15, 2020 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage...

Jan 14, 2020 04:00 pm ET

Monthly information regarding the total number of voting rights and total number of shares of the Company

Jan 08, 2020 04:30 pm ET

DBV Technologies Reports Positive Three-Year, Long-Term Data from the PEOPLE Phase III Open-Label Extension Study of Viaskin Peanut in Children with Peanut Allergy

Montrouge, France, January 8, 2020 DBV Technologies Reports Positive Three-Year, Long-Term Data from the PEOPLE Phase III Open-Label Extension Study of Viaskin Peanut in Children with Peanut Allergy Patients demonstrated durable, long-term...

Jan 02, 2020 04:30 pm ET

DBV Technologies Announces Appointment of Ramzi Benamar as Chief Financial Officer

Montrouge, France, January 2, 2020 DBV Technologies Announces Appointment of Ramzi Benamar as Chief Financial Officer DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company,...

Dec 10, 2019 04:00 pm ET

Monthly information regarding the total number of voting rights and total number of shares of the Company

Nov 19, 2019 04:00 pm ET

Monthly information regarding the total number of voting rights and total number of shares of the Company

Nov 05, 2019 04:30 pm ET

DBV Technologies to Present at the Stifel 2019 Healthcare Conference

Montrouge, France, November 5, 2019 DBV Technologies to Present at the Stifel 2019 Healthcare Conference DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today...

Oct 24, 2019 04:01 pm ET

DBV Technologies to Highlight the Burden of Peanut Allergy and Patient Experiences with Viaskin Peanut at ACAAI 2019

Montrouge, France, October 24, 2019 DBV Technologies to Highlight the Burden of Peanut Allergy and Patient Experiences with Viaskin Peanut at ACAAI 2019 New analysis evaluates quality of life in patients receiving investigational Viaskin Peanut...

Oct 16, 2019 06:30 am ET

Monthly information regarding the total number of voting rights and total number of shares of the Company

Oct 15, 2019 04:30 pm ET

DBV Technologies Announces Closing of Global Offering

Montrouge, France, October 15, 2019 DBV Technologies Announces Closing of Global Offering DBV Technologies (the “Company”) (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today...

Oct 10, 2019 01:30 am ET

DBV Technologies Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares in the Form of American Depositary Shares (ADSs

Montrouge, France, October 10, 2019 DBV Technologies Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares in the Form of American Depositary Shares (ADSs)...

Oct 09, 2019 01:30 am ET

DBV Technologies Announces Pricing of $125 million (€114 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares

Montrouge, France, October 9, 2019 DBV Technologies Announces Pricing of $125 million (€114 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares DBV Technologies (the “Company”) (Euronext: DBV – ISIN:...

Oct 08, 2019 04:18 pm ET

DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and Reports September 30, 2019 Cash Position

Montrouge, France, October 8, 2019 DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and Reports September 30, 2019 Cash Position DBV Technologies (the...

Oct 04, 2019 11:45 am ET

DBV Technologies Announces FDA Acceptance of BLA filing for Viaskin Peanut for the Treatment of Peanut Allergy

Montrouge, France, October 4, 2019DBV Technologies Announces FDA Acceptance of BLA filing for Viaskin Peanut for the Treatment of Peanut Allergy If approved, Viaskin Peanut would be the first and only epicutaneous immunotherapy indicated for this...

Oct 02, 2019 04:00 pm ET

Monthly information regarding the total number of voting rights and total number of shares of the Company

...

Ad blocking detected

DBV Technologies SA - ADR (OQ:DBVT)

Business Focus: Specialty & Advanced Pharmaceuticals